Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.8%

4 terminated/withdrawn out of 27 trials

Success Rate

84.0%

-2.5% vs industry average

Late-Stage Pipeline

22%

6 trials in Phase 3/4

Results Transparency

67%

14 of 21 completed trials have results

Key Signals

2 recruiting14 with results

Enrollment Performance

Analytics

Phase 2

11(52.4%)

Phase 3

6(28.6%)

Phase 1

2(9.5%)

N/A

2(9.5%)

21Total

Phase 2(11)

Phase 3(6)

Phase 1(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials

NCT00883480Not ApplicableCompleted

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Role: lead

NCT02941458Recruiting

Thoracic Tumours Register

Role: lead

NCT07015892Phase 3Recruiting

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Role: collaborator

NCT01652820Phase 2Completed

Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer

Role: lead

NCT03526887Phase 2Completed

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

Role: lead

NCT00503971Phase 1Terminated

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Role: lead

NCT03496766Phase 2Terminated

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Role: lead

NCT00446225Phase 3Completed

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Role: lead

NCT00478699Phase 3Completed

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

Role: lead

NCT03081689Phase 2Completed

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

Role: lead

NCT03293680Phase 2Completed

Pembrolizumab in Elderly Patients With Advanced Lung Cancer

Role: lead

NCT01088906Phase 2Terminated

Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC

Role: lead

NCT03526900Phase 2Completed

Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis

Role: lead

NCT01513174Phase 1Completed

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Role: lead

NCT03094286Phase 2Completed

Durvalumab in HIV-1 Patients With Solid Tumors

Role: lead

NCT00617656Phase 3Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma

Role: lead

NCT02709720Phase 2Completed

Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC

Role: lead

NCT03156868Completed

Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma

Role: lead

NCT00433563Not ApplicableCompleted

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer

Role: collaborator

NCT01562028Phase 2Completed

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Role: collaborator